Eli Lilly and Company (NYSE:LLY – Get Free Report)’s stock price fell 2.2% during mid-day trading on Thursday. The stock traded as low as $1,341.46 and last traded at $1,352.1810. 3,064,800 shares traded hands during mid-day trading, an increase of 4% from the average daily volume of 2,953,805 shares. The stock had previously closed at $1,382.75.
Latest Eli Lilly and Company News
Investors following LLY have been watching these news items:
- Positive Sentiment: Health Canada approved Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes, potentially broadening the drug’s use and commercial opportunity. Article: Health Canada approves Lilly’s Mounjaro
- Positive Sentiment: Lilly is expanding its oncology research through the acquisition of Calytrix Bio and a multi-target collaboration with Stipple Bio. The deals add programs and research capabilities, though their financial impact will depend on development progress. Article: Eli Lilly expands its oncology research platform
- Negative Sentiment: Healthcare ETFs reportedly sold Lilly shares, including $17.4 million from IYH and $42.3 million from XLV. These sales may add some market pressure, though they appear to be fund-position changes rather than a company-specific development. Article: IYH sells Eli Lilly shares
Analyst Upgrades and Downgrades
Several equities research analysts have issued reports on LLY shares. Weiss Ratings raised Eli Lilly and Company from a “buy (b)” rating to a “buy (b+)” rating in a research note on Friday, November 13th. Bank of America restated a “buy” rating and issued a $1,497.00 target price on shares of Eli Lilly and Company in a research report on Friday, October 30th. HSBC upped their target price on Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a research note on Thursday, September 10th. Berenberg Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price target on the stock in a research note on Tuesday, September 15th. Finally, UBS Group boosted their price objective on shares of Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the stock a “buy” rating in a report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $1,422.00.
Check Out Our Latest Stock Analysis on LLY
Eli Lilly and Company Price Performance
The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17. The business’s 50-day simple moving average is $1,268.06 and its 200-day simple moving average is $1,119.25. The stock has a market cap of $1.27 trillion, a PE ratio of 43.70, a PEG ratio of 1.71 and a beta of 0.40.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The company had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. During the same quarter in the prior year, the company earned $7.02 earnings per share. The firm’s revenue for the quarter was up 38.6% on a year-over-year basis. On average, research analysts expect that Eli Lilly and Company will post 35.72 EPS for the current fiscal year.
Eli Lilly and Company Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. Eli Lilly and Company’s payout ratio is currently 22.46%.
Insider Transactions at Eli Lilly and Company
In other news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the transaction, the executive vice president directly owned 4,137 shares in the company, valued at $5,802,225.24. This trade represents a 54.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.14% of the company’s stock.
Institutional Trading of Eli Lilly and Company
Hedge funds and other institutional investors have recently modified their holdings of the company. JDM Financial Group LLC lifted its holdings in shares of Eli Lilly and Company by 66.7% in the 3rd quarter. JDM Financial Group LLC now owns 25 shares of the company’s stock valued at $29,000 after acquiring an additional 10 shares during the last quarter. Torren Management LLC grew its stake in Eli Lilly and Company by 357.1% in the third quarter. Torren Management LLC now owns 32 shares of the company’s stock valued at $37,000 after purchasing an additional 25 shares during the last quarter. Foresight Capital Management Advisors Inc. purchased a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at $49,000. Sumitomo Mitsui Financial Group Inc. grew its position in Eli Lilly and Company by 5,100.0% during the 3rd quarter. Sumitomo Mitsui Financial Group Inc. now owns 52 shares of the company’s stock worth $60,000 after purchasing an additional 51 shares during the last quarter. Finally, Caitlin John LLC acquired a new position in shares of Eli Lilly and Company in the second quarter valued at about $64,000. 82.53% of the stock is owned by hedge funds and other institutional investors.
Eli Lilly and Company Company Profile
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
Recommended Stories
- Five stocks we like better than Eli Lilly and Company
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
